Andrew Henry - Concepedia

Author

Andrew Henry

Also Known As

A H Henry, A Henry, A. Henry, AR Henry, Andrew H Henry, Andrew H. Henry, Andrew Henry, Glenn Heigerick, Henry, A.H., andrew H Henry

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

University of Bath ImmunoGen (United States)Novartis (United States)University of Leicester Leicester Royal Infirmary

About

Andrew Henry is an author at University of Bath specializing in medicine, immunology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	256
2	Immunology	3	3	87
3	Cell Biology	1	1	12
4	Molecular Biology	1	1	55
5	Molecular Medicine	1	1	12

Andrew Henry

Publications

747

Citations

H-Index

Page 1

	Year	Citations
Humanization of murine monoclonal antibodies through variable domain resurfacing. Michael Roguska, Jim Thuesen Pedersen, C Keddy, Proceedings of the National Academy of Sciences	1994	201
Antibody-antigen interactions David M. Webster, Andrew Henry, Anthony R. Rees Current Opinion in Structural Biology	1994	132
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials Joachim Drevs, Ute Zirrgiebel, C. Schmidt-Gersbach, Annals of Oncology Tyrosine Kinase InhibitorMedicineReceptor Tyrosine KinasePharmacologySoluble Markers	2005	120
Reduced antibody response to streptavidin through site‐directed mutagenesis Damon L. Meyer, Jody Schultz, Yukang Lin, Protein Science	2001	70
A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing Michael Roguska, Jan T. Pedersen, Andrew Henry, Protein Engineering Design and Selection	1996	67
Comparison of Surface Accessible Residues in Human and Murine Immunoglobulin Fv Domains Jan T. Pedersen, Andrew Henry, Stephen Searle, Journal of Molecular Biology Immunocytochemical TechniqueImmunologyMolecular BiologySurface Accessible ResiduesImmunoglobulin E	1994	55
A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer Anne Thomas, Tanja Trarbach, C. Bartel, Annals of Oncology OncologyFolfox4 ChemotherapyMedicineColorectal CancerMolecular Oncology	2007	49
Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies Bruno Morgan, Anne Thomas, Joachim Drevs, Journal of Clinical Oncology	2003	21
Antibody modeling: Beyond homology Jan T. Pedersen, Stephen M. J. Searle, Andrew Henry, ImmunoMethods Antibody ModelingComputational BiologyImmunologyAntibody EngineeringAntibody Screening	1992	20
Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody. Scott S. Graves, S C Goshorn, Diane Stone, PubMed Tumor BiologyMurine Monoclonal AntibodyHumanized Nr-lu-13 AntibodyCompetitive ElisaImmunology	1999	12

Page 1